[Hengrui Medicine: The marketing application for Ripembotide Injection was accepted by the State Food and Drug Administration] On September 9, Hengrui Medicine (600276.SH) announced that the company's subsidiary Fujian Shengdi Medicine received the "Notice of Acceptance" from the State Food and Drug Administration. The application for marketing authorization of Ripembotide Injection was accepted, and the proposed indication is blood sugar control in adults with type 2 diabetes. The drug is a GLP-1 and GIP dual agonist independently developed by Hengrui. Two key phase III clinical studies have shown that the average reduction in HbA1c in the 4 mg group of Ripprotide Injection reached 2.67%-2.78%. Compared with the 1 mg group of Semaglutide Injection, the primary endpoints were non-inferior, with the 4 mg group having superior hypoglycemic effect. Up to now, the cumulative R&D investment in related projects is approximately 746 million yuan.